Lanadelumab Reduces Pediatric HAE Attacks 95% in Real-World Analysis

A real-world study presented at the ACAAI 2026 meeting found that the drug lanadelumab reduced hereditary angioedema (HAE) attacks by 95% in pediatric patients. The findings support the effectiveness of the treatment following the FDA's label expansion for younger children.
Why it matters
This data provides critical evidence for the efficacy of prophylactic treatments in improving the quality of life for children suffering from rare genetic conditions.
Real-world data presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting show lanadelumab (Takhzyro) prophylaxis reduced attack frequency by 95% in pediatric patients with hereditary angioedema (HAE), according to a retrospective chart review.
Before the US Food and Drug Administration (FDA) expanded the lanadelumab label to children aged ≥ 2 years in February 2023, routine prophylaxis for children aged 6 to <12 years required dosing every 3 to 4 days, and no prophylactic option was approved for children aged 2 to 5 years.1 The expanded approval was supported by safety, pharmacokinetic, and pharmacodynamic data from the phase 3 SPRING study, along with efficacy data extrapolated from the phase 3 HELP study.1
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in